Company / Working Capital
Cogent Biosciences, Inc. Working Capital History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$846.4M
FY2025
5-year range
$205.6M / $846.4M
FY2021-FY2025
Trend
+251.6%
vs FY2024
Sector context
#47 of 213
Health Care
What the data says
Working Capital changed +252% YoY in FY2025, a notable deviation from the 8-year average annual change of +129%.
Based on SEC 10-K filings.
$846M in FY2025 with a 5-year CAGR of +29.6%. Top quartile in the Health Care sector.
Improved from $233M to $846M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +52.6%
- 5-Year CAGR
- +29.6%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 213This company $846.4M Sector average $934.6M
▼
-9.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.6%, indicating consistent growth.
- In FY2025, working capital increased 251.6% year-over-year.
- Ranks #47 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $846.4M | +251.6% |
| FY2024 | $240.8M | +3.5% |
| FY2023 | $232.6M | -2.3% |
| FY2022 | $238.1M | +15.8% |
| FY2021 | $205.6M | -11.3% |
| FY2020 | $231.8M | +747.8% |
| FY2019 | $27.3M | -51.2% |
| FY2018 | $56.1M | +79.7% |
| FY2017 | $31.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026